Partenariat

Articles

• Relocation of the company to support its development
  1 October 2019, by Elodie DORMES

  Relocation of Vect-Horus in medical faculty of the La Timone campus to maintain strong collaborative working environment with its historical partners and support its development.

• Vect-Horus further strengthens leadership with appointment of strategy and finance executive Jérôme Berger to its Board of Directors
  3 February 2025, by Emmanuelle BETTENDORF

  We are excited that Jerome Berger is joining our Board of Directors!
  Jerome brings vast expertise in strategy, finance, and venture capital in the technology and life sciences sectors, which will be invaluable as Vect-Horus accelerates its growth and development.
  “Jerome’s unparalleled experience in strategy, venture capital and global financing, coupled with his strong background in digital health and life sciences, will be invaluable in supporting the development of Vect-Horus as we (…)

• Vect-Horus is a partner laureate of the ANR MALZ 2010 call for proposals
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2010 call for proposals and will be involved in the ADHOC project coordinated by the UMR7259 laboratory (Coordinator, Pr. François Féron).
  This project received support (label) from the EUROBIOMED Biocluster.

• Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics
  1 November 2023, by Emmanuelle BETTENDORF

  Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S. This agreement provides Novo Nordisk with worldwide, exclusive license to use Vect-Horus platform technology ”VECTrans”; for delivery of cargos directed against specified targets . Novo Nordisk has an option to add additional targets to the (…)

• Vect-Horus announces the signing of a scientific collaboration agreement with SERVIER
  28 January 2019, by Jonathan NOWAK

  The two companies intend to enter in a collaboration agreement to develop new therapeutic molecules in the field of central nervous system (CNS) diseases
  VECT-HORUS, a biotechnology company that designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents, notably in the brain, is announcing today the signing of a scientific collaboration agreement with SERVIER. The companies did not disclose the financial terms of this agreement. This collaboration is part (…)

• Vect-Horus announces Collaboration and Option Agreement with ASTELLAS Pharma
  4 June 2019, by Jonathan NOWAK

  Vect-Horus announced today the signing of the Research Collaboration and Option Agreement (the “Agreement”) with Astellas Pharma Inc., a Japan based pharmaceutical company (“Astellas”). Vect-Horus will use its proprietary technology VECTrans® to transport Astellas’ antibody to the brain for the treatment of CNS diseases.

• Vect-Horus announces the signing of a scientific collaboration agreement with SANOFI in the field of neurodegenerative diseases
  28 January 2019, by Jonathan NOWAK

  The goal of this collaboration is to use VECT-HORUS’ proprietary technology to transport therapeutic antibodies into the brain for the treatment of a neurodegenerative disease.

• Signature of a Research Common Lab with the Institute for NeuroPhysiopathology (UMR7051 CNRS-AMU)
  28 January 2019, by Jonathan NOWAK

  Since its incorporation in 2005 VECT-HORUS is a leading partner of the French academic institutions CNRS and Aix-Marseille University. Indeed, the company as a spin-off of the NICN (UMR7259 CNRS-AMU) now Institute for NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, develops inventions and technologies derived from the “BBB and Neuroinflammation Team”. VECT-HORUS has established a long-term highly efficient collaboration with this (…)

• Vect-Horus is a partner laureate of the ANR RPIB Call 2013 for proposals
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) RPIB Call 2013 for proposals and will be involved in the VEC2Brain project involving 3 academic laboratories. The project will be coordinated by Dr Michel Khrestchatisky, Director of the UMR7259 laboratory (CNRS and Aix-Marseille University) and involves the U705 laboratory (Director, Pr. Jean-Michel Scherrmann) of INSERM and the SIMOPRO laboratory (Director Dr. Vincent Dive) of the CEA. This project received (…)